SG169375A1 - Yeast-based vaccine for inducing an immune response - Google Patents
Yeast-based vaccine for inducing an immune responseInfo
- Publication number
- SG169375A1 SG169375A1 SG201100779-6A SG2011007796A SG169375A1 SG 169375 A1 SG169375 A1 SG 169375A1 SG 2011007796 A SG2011007796 A SG 2011007796A SG 169375 A1 SG169375 A1 SG 169375A1
- Authority
- SG
- Singapore
- Prior art keywords
- immune response
- eliciting
- compositions
- useful
- yeast
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16311—Influenzavirus C, i.e. influenza C virus
- C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76502506P | 2006-02-02 | 2006-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG169375A1 true SG169375A1 (en) | 2011-03-30 |
Family
ID=38345897
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG201100779-6A SG169375A1 (en) | 2006-02-02 | 2007-02-02 | Yeast-based vaccine for inducing an immune response |
SG10201402236VA SG10201402236VA (en) | 2006-02-02 | 2007-02-02 | Yeast-based vaccine for inducing an immune response |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201402236VA SG10201402236VA (en) | 2006-02-02 | 2007-02-02 | Yeast-based vaccine for inducing an immune response |
Country Status (14)
Country | Link |
---|---|
US (2) | US7736642B2 (ja) |
EP (2) | EP1988919A4 (ja) |
JP (3) | JP5198290B2 (ja) |
KR (2) | KR20140029551A (ja) |
CN (2) | CN104826102A (ja) |
AU (1) | AU2007212076B2 (ja) |
BR (1) | BRPI0706913A2 (ja) |
CA (1) | CA2638815A1 (ja) |
IL (2) | IL193196A (ja) |
IN (1) | IN2014DN08830A (ja) |
MX (1) | MX2008009929A (ja) |
SG (2) | SG169375A1 (ja) |
TW (2) | TW201412329A (ja) |
WO (1) | WO2007092792A2 (ja) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7083787B2 (en) * | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
US8343502B2 (en) * | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
EP1581174B1 (en) * | 2002-12-16 | 2018-04-25 | GlobeImmune, Inc. | Yeast-based vaccines as immunotherapy |
CA2614884A1 (en) * | 2005-07-11 | 2007-01-18 | Globeimmune, Inc | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
US20070172503A1 (en) * | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
JP5198290B2 (ja) * | 2006-02-02 | 2013-05-15 | グローブイミューン,インコーポレイテッド | 免疫反応を誘発する酵母ベースワクチン |
GB0613977D0 (en) | 2006-02-07 | 2006-08-23 | Peptcell Ltd | Peptide sequences and compositions |
US9101578B2 (en) * | 2006-05-01 | 2015-08-11 | Technovax, Inc. | Polyvalent influenza virus-like particle (VLP) compositions |
EP1998814A4 (en) * | 2006-05-11 | 2010-06-16 | Novavax Inc | NEW VACCINES AGAINST INFLUENZA M2 |
CA2657849A1 (en) * | 2006-05-18 | 2008-05-08 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
WO2008097863A2 (en) | 2007-02-02 | 2008-08-14 | Globeimmune, Inc. | Methods for producing yeast-based vaccines |
CN101730542A (zh) * | 2007-03-19 | 2010-06-09 | 环球免疫公司 | 用于靶向消除癌症靶向疗法的突变逃逸的组合物和方法 |
US20100285050A1 (en) | 2007-10-05 | 2010-11-11 | Isis Innovation Limited | Compositions and Methods |
GB0719526D0 (en) * | 2007-10-05 | 2007-11-14 | Isis Innovation | Compositions and methods |
US20110177122A1 (en) * | 2008-09-26 | 2011-07-21 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | Dna prime/activated vaccine boost immunization to influenza virus |
JP5759980B2 (ja) * | 2009-04-17 | 2015-08-05 | グローブイミューン,インコーポレイテッド | 癌および感染症に対する免疫療法組成物の組み合わせ |
AU2010250780A1 (en) * | 2009-05-18 | 2012-01-12 | Panacea Biotec Ltd | Universal influenza vaccine based on recombinant modified vaccinia Ankara virus (MVA) |
EP2477647B1 (en) | 2009-09-14 | 2016-01-13 | The Regents of the University of Colorado | Modulation of yeast-based immunotherapy products and responses |
US20120015346A1 (en) * | 2010-07-08 | 2012-01-19 | New York Medical College | Influenza virus detection and diagnosis |
US10226527B2 (en) * | 2010-10-04 | 2019-03-12 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
JP5933565B2 (ja) * | 2010-10-15 | 2016-06-15 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換え改変ワクシニアウイルスアンカラインフルエンザワクチン |
WO2012083302A2 (en) * | 2010-12-17 | 2012-06-21 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
AU2012212463B2 (en) * | 2011-01-31 | 2016-07-07 | Nanotherapeutics, Inc. | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses |
AP2013007110A0 (en) | 2011-02-12 | 2013-09-30 | Globeimmune Inc | Yeast-based therapeutic for chronic hepatitis B infection |
HUE033491T2 (en) | 2011-03-17 | 2017-12-28 | Globeimmune Inc | Yeast-Brachyury immunotherapy |
CN103732249A (zh) * | 2011-05-23 | 2014-04-16 | 威斯特解剖及生物研究所 | 含有经修饰腺病毒载体的流感疫苗 |
JP2014523878A (ja) * | 2011-06-14 | 2014-09-18 | グローブイミューン,インコーポレイテッド | D型肝炎ウイルス感染の治療又は予防のための酵母ベースの組成物及び方法 |
KR20140047069A (ko) * | 2011-06-20 | 2014-04-21 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 계산에 최적화된 광범위 반응을 나타내는 h1n1 인플루엔자를 위한 항원 |
MX352892B (es) | 2011-08-17 | 2017-12-13 | Globeimmune Inc | Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas. |
EP2591798B1 (en) * | 2011-11-09 | 2014-11-19 | Werner Lubitz | Vaccine for use in tumor immunotherapy |
DE102011121069A1 (de) * | 2011-12-13 | 2013-06-13 | Martin-Luther-Universität Halle-Wittenberg | Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene |
WO2014003853A1 (en) | 2012-06-26 | 2014-01-03 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
US9744193B2 (en) | 2012-09-06 | 2017-08-29 | Orbis Health Solutions Llc | Tumor lysate loaded particles |
JP5954079B2 (ja) | 2012-09-25 | 2016-07-20 | ソニー株式会社 | 培養観察装置及び培養観察方法 |
AU2013359469B2 (en) * | 2012-12-10 | 2019-05-16 | Seattle Biomedical Research Institute | Cell-free biofragment compositions and related systems, devices, and methods |
US9669091B2 (en) * | 2013-03-15 | 2017-06-06 | Inovio Pharmaceuticals, Inc. | Vaccines having an antigen and interleukin-23 as an adjuvant |
JP6509808B2 (ja) | 2013-03-19 | 2019-05-08 | グローブイミューン,インコーポレイテッド | 脊索腫のための酵母系免疫療法 |
US9782473B2 (en) | 2013-03-26 | 2017-10-10 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
JP2014210747A (ja) * | 2013-04-19 | 2014-11-13 | アンジェスMg株式会社 | 細胞性免疫誘導能が改善された経口ワクチン |
WO2015031778A2 (en) * | 2013-08-30 | 2015-03-05 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of tuberculosis |
EP3092004A4 (en) | 2014-01-06 | 2017-02-22 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
CN106456532B (zh) | 2014-03-05 | 2020-07-24 | 奥比思健康解决方案有限责任公司 | 使用酵母细胞壁颗粒的疫苗递送系统 |
KR102409372B1 (ko) * | 2014-04-11 | 2022-06-16 | 글로브이뮨 | 효모 면역 요법 및 타입 i 인터페론 감도 |
CN105233302B (zh) * | 2014-07-10 | 2018-10-19 | 中国人民解放军军事医学科学院生物工程研究所 | 一种流感血凝素糖蛋白多聚物纳米颗粒的制备方法 |
US10695417B2 (en) | 2015-01-09 | 2020-06-30 | Etubics Corporation | Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein |
WO2016168187A1 (en) * | 2015-04-13 | 2016-10-20 | The Regents Of The University Of Michigan | Virus-like particles |
KR20180054587A (ko) | 2015-08-03 | 2018-05-24 | 글로브이뮨 | 변형된 효모-브라큐리 면역치료학적 조성물 |
EP3334455A4 (en) * | 2015-08-11 | 2019-08-21 | Orbis Health Solutions LLC | STRATEGY FOR BACTERIAL AND VIRAL VACCINATION |
GB2552441A (en) * | 2015-10-22 | 2018-01-31 | Royal Veterinary College | Methods |
EP3195878A1 (en) | 2016-01-22 | 2017-07-26 | Werner Lubitz | Bacterial ghosts for the treatment of cancer |
KR20180117227A (ko) | 2016-03-24 | 2018-10-26 | 난트셀, 인크. | 네오에피토프 제시를 위한 시퀀스들 및 시퀀스 배열들 |
US11779637B2 (en) | 2017-04-24 | 2023-10-10 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
AU2018388102A1 (en) | 2017-12-21 | 2020-07-16 | Green Biomed, Inc. | Cross-immunizing antigen vaccine and method for preparation thereof |
DE102017012109A1 (de) | 2017-12-27 | 2019-06-27 | Martin-Luther-Universität Halle-Wittenberg | Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis |
EP3793576A4 (en) * | 2018-05-15 | 2022-04-06 | Globeimmune, Inc. | RECOMBINANT YEAST LYSATES FOR INDUCING CELLULAR IMMUNE RESPONSE |
WO2020051766A1 (zh) | 2018-09-11 | 2020-03-19 | 上海市公共卫生临床中心 | 一种广谱抗流感疫苗免疫原及其应用 |
WO2020061203A1 (en) | 2018-09-21 | 2020-03-26 | Nantcell, Inc. | Methods and compositions for modulating myeloid-derived suppressor cells |
CA3138174A1 (en) * | 2019-05-21 | 2020-11-26 | David James O'hagan | Yeast-based oral vaccination |
JP2023515355A (ja) * | 2020-02-11 | 2023-04-13 | サイトナス セラピューティクス,インク. | 高速ワクチンプラットフォーム |
US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
AU2021254753A1 (en) | 2020-04-14 | 2022-08-25 | Nantcell, Inc. | Yeast lysate COVID-19 vaccine |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830463A (en) * | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
CA2180965C (en) * | 1994-01-11 | 2010-05-11 | Tom Maria Deroo | Influenza vaccine |
US5691189A (en) * | 1994-01-19 | 1997-11-25 | Bristol-Myers Squibb Company | Saccharomyces cerevisiae expressing M2 protein of influenza A virus |
US6696251B1 (en) * | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US20020044948A1 (en) * | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
WO2002000885A2 (en) * | 2000-06-23 | 2002-01-03 | American Cyanamid Company | Assembly of wild-type and chimeric influenza virus-like particles (vlps) |
US7083787B2 (en) | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
US20030008000A1 (en) * | 2001-03-08 | 2003-01-09 | Wong Jonathan P. | DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus |
US20030202982A1 (en) * | 2001-08-15 | 2003-10-30 | Birkett Ashley J. | Influenza immunogen and vaccine |
US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
EP1581174B1 (en) | 2002-12-16 | 2018-04-25 | GlobeImmune, Inc. | Yeast-based vaccines as immunotherapy |
US8592197B2 (en) * | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
WO2005116270A2 (en) * | 2004-05-18 | 2005-12-08 | Vical Incorporated | Influenza virus vaccine composition and method of use |
WO2006032039A2 (en) | 2004-09-17 | 2006-03-23 | University Of Massachusetts | Compositions and their uses for lysosomal enzyme deficiencies |
JP5198290B2 (ja) * | 2006-02-02 | 2013-05-15 | グローブイミューン,インコーポレイテッド | 免疫反応を誘発する酵母ベースワクチン |
-
2007
- 2007-02-02 JP JP2008553534A patent/JP5198290B2/ja not_active Expired - Fee Related
- 2007-02-02 IN IN8830DEN2014 patent/IN2014DN08830A/en unknown
- 2007-02-02 TW TW102144486A patent/TW201412329A/zh unknown
- 2007-02-02 SG SG201100779-6A patent/SG169375A1/en unknown
- 2007-02-02 CN CN201510122553.9A patent/CN104826102A/zh not_active Withdrawn
- 2007-02-02 WO PCT/US2007/061572 patent/WO2007092792A2/en active Application Filing
- 2007-02-02 MX MX2008009929A patent/MX2008009929A/es active IP Right Grant
- 2007-02-02 SG SG10201402236VA patent/SG10201402236VA/en unknown
- 2007-02-02 EP EP07717549A patent/EP1988919A4/en not_active Withdrawn
- 2007-02-02 KR KR1020147004408A patent/KR20140029551A/ko not_active Application Discontinuation
- 2007-02-02 TW TW096103976A patent/TW200806316A/zh unknown
- 2007-02-02 KR KR20087020923A patent/KR101492524B1/ko active IP Right Grant
- 2007-02-02 CN CN200780009861.4A patent/CN101405026B/zh not_active Expired - Fee Related
- 2007-02-02 US US11/670,902 patent/US7736642B2/en not_active Expired - Fee Related
- 2007-02-02 EP EP11180828.3A patent/EP2468296A3/en not_active Withdrawn
- 2007-02-02 CA CA002638815A patent/CA2638815A1/en not_active Withdrawn
- 2007-02-02 BR BRPI0706913-8A patent/BRPI0706913A2/pt not_active Application Discontinuation
- 2007-02-02 AU AU2007212076A patent/AU2007212076B2/en not_active Ceased
-
2008
- 2008-07-31 IL IL193196A patent/IL193196A/en active IP Right Review Request
-
2010
- 2010-04-16 US US12/762,221 patent/US20100196411A1/en not_active Abandoned
-
2012
- 2012-11-29 JP JP2012260860A patent/JP2013075899A/ja active Pending
-
2014
- 2014-05-08 IL IL232518A patent/IL232518A0/en unknown
- 2014-11-13 JP JP2014230982A patent/JP2015038147A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
KR101492524B1 (ko) | 2015-02-12 |
IL193196A (en) | 2015-01-29 |
TW201412329A (zh) | 2014-04-01 |
EP1988919A2 (en) | 2008-11-12 |
WO2007092792A3 (en) | 2008-02-28 |
TW200806316A (en) | 2008-02-01 |
US7736642B2 (en) | 2010-06-15 |
JP2015038147A (ja) | 2015-02-26 |
AU2007212076B2 (en) | 2012-10-18 |
US20100196411A1 (en) | 2010-08-05 |
EP2468296A3 (en) | 2013-12-04 |
KR20080089671A (ko) | 2008-10-07 |
CN104826102A (zh) | 2015-08-12 |
CN101405026B (zh) | 2015-04-22 |
WO2007092792A2 (en) | 2007-08-16 |
JP2009528987A (ja) | 2009-08-13 |
SG10201402236VA (en) | 2014-08-28 |
JP2013075899A (ja) | 2013-04-25 |
IL193196A0 (en) | 2011-08-01 |
MX2008009929A (es) | 2008-10-01 |
KR20140029551A (ko) | 2014-03-10 |
BRPI0706913A2 (pt) | 2011-04-12 |
IL232518A0 (en) | 2014-06-30 |
JP5198290B2 (ja) | 2013-05-15 |
AU2007212076A1 (en) | 2007-08-16 |
EP1988919A4 (en) | 2009-06-10 |
CN101405026A (zh) | 2009-04-08 |
EP2468296A2 (en) | 2012-06-27 |
IN2014DN08830A (ja) | 2015-07-10 |
US20080003239A1 (en) | 2008-01-03 |
CA2638815A1 (en) | 2007-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG169375A1 (en) | Yeast-based vaccine for inducing an immune response | |
AU2009326524A8 (en) | Use of Flt3 ligand for strengthening immune responses in RNA immunization | |
WO2007024941A3 (en) | Polyvalent vaccine | |
MXPA05013973A (es) | Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos. | |
WO2007120673A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
WO2010019262A3 (en) | Polyvalent vaccine | |
WO2006113214A3 (en) | Vaccine against pandemic strains of influenza viruses | |
SG158154A1 (en) | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes | |
MY159500A (en) | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response | |
MY149604A (en) | C.perfringens alpha toxoid vaccine | |
GB2434367A (en) | Improved vaccines | |
WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
EP1594536A4 (en) | ADJUVANT INFLUENZA VACCINE | |
WO2008148057A3 (en) | Cationic lipids compositions and methods for enhancing immune responses to vaccines | |
WO2011106607A3 (en) | Subunit vaccines for herpes viruses and methods of use | |
MX2017013564A (es) | Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual. | |
MX2016001695A (es) | Composiciones inmunogenas de combinacion. | |
WO2012074881A3 (en) | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response | |
WO2007120603A3 (en) | Immunogenic bcr-abl peptides and methods of use thereof | |
WO2010080188A3 (en) | Epitope targeted anthrax vaccine | |
WO2015048796A3 (en) | Mosaic hiv envelope immunogenic polypeptides | |
WO2007120860A3 (en) | Nanoemulsion vaccines | |
SG147465A1 (en) | Vaccine | |
TN2014000393A1 (en) | Modified marek's disease virus, and vaccines made therefrom |